Mangoceuticals, Inc. (MGRX) Stock Forecast Nov. 6, 2026
Analysis updated on Nov. 6, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Mangoceuticals, Inc. (MGRX) stock forecast summary
Our AI scores Mangoceuticals, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Mangoceuticals, Inc. is a small-cap company with a market capitalization of $4M. It ranks number 12 by market capitalization among the 13 Services-Misc Health & Allied Services, NEC issuers in our coverage with a current forecast. Its Net Margin of -6539.3% is the lowest of the 9 peers that report one. Its Current Ratio of 0.18x is the lowest of the 11 peers that report one.
For MGRX, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -28.0%, measured on 319 forecast dates between 2023-05-12 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -35.0%, measured on 362 forecast dates between 2023-05-12 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +3.1%, buy ≥ +1.5%, sell < -0.5%, strong sell < -1.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-06 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, MGRX included.
MGRX price chart and AI forecast
How MGRX ranks among 5150 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Mangoceuticals, Inc. (MGRX) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Misc Health & Allied Services, NEC peers listed below that report each metric.
Valuation & Market
| Metric | MGRX | Rank |
|---|---|---|
| Market Cap | $4M | 12/13 |
| P/B Ratio | 0.33x | 8/9 |
| EPS | $-1.35 | – |
| Book Value/Share | $0.58 | – |
Profitability & Margins
| Metric | MGRX | Rank |
|---|---|---|
| ROE | -159.3% | 6/6 |
| ROA | -140.8% | 7/8 |
| ROIC | -132.8% | 8/8 |
| Gross Margin | 70.2% | 2/6 |
| Operating Margin | -5562.1% | 8/9 |
| Net Margin | -6539.3% | 9/9 |
| EBT Margin | -5817.7% | 9/10 |
Financial Health
| Metric | MGRX | Rank |
|---|---|---|
| Current Ratio | 0.18x | 11/11 |
| D/E Ratio | 0.13x | 9/10 |
| Financial Leverage | 1.13x | 8/9 |
| Working Capital | -$1M | 9/11 |
Cash Flow
| Metric | MGRX | Rank |
|---|---|---|
| Operating Cash Flow | -$4M | 7/10 |
Income Statement
| Metric | MGRX | Rank |
|---|---|---|
| Operating Income | -$17M | 8/9 |
| Net Income | -$20M | 8/9 |
| Cost of Goods Sold | $40K | 6/7 |
Dividend & Shareholder Information
| Metric | MGRX | Rank |
|---|---|---|
| Shares Outstanding | 22M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $250K | 1.8% of assets |
| Cash & Short-term Investments | $230K | 1.6% of assets |
| Total Liabilities | $2M | 11.6% of assets |
MGRX quarterly financials and insider trading
Mangoceuticals, Inc. (MGRX) industry peers
Companies classified under the same SEC industry code as Mangoceuticals, Inc. (Services-Misc Health & Allied Services, NEC): 13 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| MGRX Mangoceuticals, Inc. | $4M | |
| FMS Fresenius Medical Care Ag | $12.15B | |
| DVA Davita Inc. | $12.04B | |
| SHC Sotera Health Co | $4.53B | |
| PGNY Progyny, Inc. | $2.64B | |
| AGL Agilon Health, Inc. | $1.90B | |
| VMD Viemed Healthcare, Inc. | $348M | |
| PARK Park Dental Partners, Inc. | $96M | |
| MRAI Marpai, Inc. | $74M | |
| CCEL Cryo Cell International Inc | $40M | |
| PFHO Pacific Health Care Organization Inc | $13M | |
| NIVF Newgenivf Group Ltd | $5M | |
| BRTX Biorestorative Therapies, Inc. | $2M |
Where MGRX sits on the market map
Mangoceuticals, Inc. (MGRX) stock news
Loading...
Mangoceuticals, Inc. (MGRX) stock forecast FAQ
What is the Mangoceuticals, Inc. (MGRX) stock forecast?
Our AI scores Mangoceuticals, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
How accurate are Mangoceuticals, Inc. stock predictions?
For MGRX, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -28.0%, measured on 319 forecast dates between 2023-05-12 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -35.0%, measured on 362 forecast dates between 2023-05-12 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Mangoceuticals, Inc. forecasts updated?
Mangoceuticals, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 6, 2026.
Which companies are Mangoceuticals, Inc.'s industry peers?
13 issuers in our coverage, MGRX included, share the SEC industry code Services-Misc Health & Allied Services, NEC. The largest are: Fresenius Medical Care Ag (FMS), Davita Inc. (DVA), Sotera Health Co (SHC), Progyny, Inc. (PGNY), Agilon Health, Inc. (AGL), Viemed Healthcare, Inc. (VMD).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.